PDL BioPharma

$2.59
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.03 (+1.17%) Today
$0.00 (0.00%) As of 10:00 PM UTC after-hours

Why Robinhood?

You can buy or sell PDL BioPharma and other stocks, options, and ETFs commission-free!

About PDLI

PDL BioPharma, Inc. produces and markets biopharmaceutical products. It operates through the following segments: Income Generating Assets, Pharmaceutical, and Medical Devices. The Income Generating Assets segment consists of revenues derived from notes and other long-term receivables, royalty rights-at fair value, equity investments, and royalties from issued patents in the United States and elsewhere. The Pharmaceutical segment covers revenues from branded prescription medicine products being sold under the name Tekturna and Tekturna HCT in the United States, and Rasilez and Rasilez HCT for the rest of the world. The Medical Devices segment handles revenues from the LENSAR Laser System sales. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Incline Village, NV. The listed name for PDLI is PDL BioPharma, Inc. Common Stock.

CEO
Dominique P. Monnet
Employees
75
Headquarters
Incline Village, Nevada
Founded
1986
Market Cap
295.85M
Price-Earnings Ratio
Dividend Yield
Average Volume
1.84M
High Today
$2.62
Low Today
$2.54
Open Price
$2.56
Volume
648.48K
52 Week High
$3.86
52 Week Low
$2.09

Collections

PDLI Earnings

-$0.20
-$0.10
$0.01
$0.11
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 10, After Hours

You May Also Like